Table 1.
Value of BAP1 versus PBRM1 in localized disease.
| Author [Ref.] | Year | Country | Gender M(%)/F(%) | Age (y) |
N |
BAP1 MT(%) |
PBRM1 MT(%) |
Tech | Survival Efficacy Parameters | |
|---|---|---|---|---|---|---|---|---|---|---|
| RFS (HR/ p) | OS (HR/ p) | |||||||||
| Kapur [40] | 2013 | USA | 80(55)/65(45) | 62 | 145 | 21(14) | 78(54) | NGS | NA |
BAP1 MT: 4.6; PBRM1 MT: 10.6 (2.7/0.044) |
| Gossage [41] | 2014 | UK | 83(63)/49(37) | 62 | 132 | 14(11) | 42(33) | NGS |
BAP1 MT: 1.2 a; PBRM1 MT: 4.9 a (n.sp./0.059) |
n.sp. (n.sp./NS) |
M: male patients. F: female patients. Age: median age. y: years. N: number of patients. MT: mutant patients. Tech: Technique. NGS: next-generation sequencing. RFS: recurrence-free-survival in years. HR: hazard ratio. OS: overall survival in years. NS: non statistically significant. NA: not assessed. n.sp.: not specified. a 75th percentile for survival.